Literature DB >> 12730361

Oxidative stress-induced homologous recombination as a novel mechanism for phenytoin-initiated toxicity.

Louise M Winn1, Perry M Kim, Jac A Nickoloff.   

Abstract

Although the mechanism(s) of phenytoin-initiated toxicity is unknown, phenytoin can be enzymatically bioactivated to a reactive intermediate leading to increased formation of reactive oxygen species, which can damage essential macromolecules, including DNA. The oxidation of DNA can induce DNA double-strand breaks (DSBs), which may be repaired through homologous recombination. Increased levels of DSBs may induce hyper-recombination, leading to deleterious genetic changes. We hypothesize that these genetic changes mediate phenytoin-initiated toxicity. To investigate this hypothesis we used a Chinese hamster ovary cell line containing a neo direct repeat recombination substrate to determine whether phenytoin-initiated DNA oxidation increases homologous recombination. Cells were treated with 0 to 800 microM phenytoin for 5 or 24 h, and homologous recombination frequencies and recombinant product structures were determined. Phenytoin-initiated DNA oxidation was determined by measuring the formation of 8-hydroxy-2'-deoxyguanosine. We demonstrate that phenytoin increases both DNA oxidation and homologous recombination in a concentration- and time-dependent manner. All recombination products analyzed arose via gene conversion without associated crossover. Our data demonstrate that phenytoin-initiated DNA damage can induce homologous recombination, which may be a novel mechanism mediating phenytoin-initiated toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730361     DOI: 10.1124/jpet.103.052639

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Oxidative stress, unfolded protein response, and apoptosis in developmental toxicity.

Authors:  Allison Kupsco; Daniel Schlenk
Journal:  Int Rev Cell Mol Biol       Date:  2015-03-11       Impact factor: 6.813

2.  UV radiation induces delayed hyperrecombination associated with hypermutation in human cells.

Authors:  Stephen T Durant; Kimberly S Paffett; Meena Shrivastav; Graham S Timmins; William F Morgan; Jac A Nickoloff
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

3.  Anticonvulsant and antioxidant actions of trimetazidine in pentylenetetrazole-induced kindling model in mice.

Authors:  Seema Jain; Nidhi Bharal; Sonam Khurana; Pramod Kumari Mediratta; Krishna Kishore Sharma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-12       Impact factor: 3.000

4.  Ameliorative Effects of α-Tocopherol and/or Coenzyme Q10 on Phenytoin-Induced Cognitive Impairment in Rats: Role of VEGF and BDNF-TrkB-CREB Pathway.

Authors:  Marwa M Nagib; Mariane G Tadros; Rania M Rahmo; Nagwa Ali Sabri; Amani E Khalifa; Somaia I Masoud
Journal:  Neurotox Res       Date:  2018-10-29       Impact factor: 3.911

5.  Genetically induced redox stress occurs in a yeast model for Roberts syndrome.

Authors:  Michael G Mfarej; Robert V Skibbens
Journal:  G3 (Bethesda)       Date:  2022-02-04       Impact factor: 3.542

6.  Trimetazidine, an Anti-Ischemic Drug, Reduces the Antielectroshock Effects of Certain First-Generation Antiepileptic Drugs.

Authors:  Kinga Borowicz-Reutt; Monika Banach
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

7.  Susceptibility to DNA damage as a molecular mechanism for non-syndromic cleft lip and palate.

Authors:  Gerson Shigeru Kobayashi; Lucas Alvizi; Daniele Yumi Sunaga; Philippa Francis-West; Anna Kuta; Bruno Vinícius Pimenta Almada; Simone Gomes Ferreira; Leonardo Carmo de Andrade-Lima; Daniela Franco Bueno; Cássio Eduardo Raposo-Amaral; Carlos Frederico Menck; Maria Rita Passos-Bueno
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

Review 8.  The relationship between COPD and lung cancer.

Authors:  A L Durham; I M Adcock
Journal:  Lung Cancer       Date:  2015-08-29       Impact factor: 5.705

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.